Actively Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Oral Denifanstat for Moderate to Severe Acne Vulgaris
Led by Sagimet Biosciences Inc. · Updated on 2026-10-29
800
Participants Needed
23
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of denifanstat compared with a matching placebo in people aged 12 years and older who have moderate to severe acne vulgaris. This Phase 3 trial aims to better understand how denifanstat might treat this condition by comparing it to a placebo over a 12-week period. Participants will receive either oral denifanstat or an oral placebo once daily during the 12-week treatment phase. After this, about 530 participants may choose to join an open-label extension phase, receiving denifanstat for an additional 40 weeks. The study uses a randomized, double-blind design to fairly compare the effects of the treatment and placebo. During the study, participants will be assessed for improvements in their acne using specific scoring systems and lesion counts at Week 12. Safety and response to treatment will be monitored throughout. The total participation time may extend up to 52 weeks for those in the extension phase, allowing researchers to gather detailed information on denifanstats impact and safety over time.
CONDITIONS
Brief Title
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here